Prostate cancer is not one disease. It is three biologically distinct diseases sharing a diagnostic label, and current clinical practice is structured for the rarest and most aggressive of the three.
Prostate cancer is the most common cancer in men. It is also the disease where the gap between population statistics and individual biology is most consequential, most documented, and most consistently overlooked.
The diagnosis is not the disease.
This is the fact that changes everything about how prostate cancer should be understood, and the fact that the standard clinical encounter most consistently fails to communicate.
Autopsy studies of men who died from unrelated causes find histological evidence of prostate cancer in approximately 30% of men in their forties, rising to over 80% of men in their eighties. The vast majority had no clinical diagnosis, no symptoms, and no knowledge that the cancer existed. They died with prostate cancer, not of it.
This is not a statistical curiosity. It is the defining biological fact about the disease. The moment a biopsy returns positive and a man is told he has cancer does not necessarily represent the onset of a dangerous disease. In most cases, it represents the detection of a process that has been present for years or decades, that may progress slowly or not at all, and whose future behaviour is determined by conditions that the diagnostic moment captures only partially and imperfectly.
The Gleason score describes the cellular architecture of the sampled tissue at the moment of biopsy. It does not describe the biological environment in which that tissue is embedded, the hormonal ecology shaping its behaviour, the metabolic field conditions determining whether the cancer will remain stable or progress, or the individual history that produced the specific biological state the biopsy has sampled.
Two men receive the same diagnosis: Gleason 3+4, PSA 6.2, one positive core out of twelve, clinical stage T2a. By every population metric, they are the same patient. Their risk categories are identical. The statistical tables that estimate their probability of progression apply to both. And yet their biology, the metabolic field in which their cancer is developing, the hormonal environment it is navigating, the inflammatory conditions either suppressing or driving it, the immune surveillance either containing or permitting it, may differ as substantially as their fingerprints. The population tool has classified them identically. The individual biology is not the same.
The diagnosis is a moment in a process. The process has a biological context. The biological context is individually specific. Population statistics describe the distribution of outcomes across men who shared the diagnostic moment. They do not describe what will happen to either of these two specific men.
The metabolic field
Prostate cancer does not develop in a biological vacuum. It develops in a metabolic environment, defined by insulin sensitivity, inflammatory tone, mitochondrial quality, and the oscillation between cellular growth and repair, that either constrains it or enables it.
The epidemiological evidence is substantial. Obesity, insulin resistance, and metabolic syndrome are associated with higher Gleason grades, higher rates of biochemical recurrence after treatment, and worse outcomes across multiple endpoints. These associations reflect a genuine biological relationship between the systemic metabolic environment and the behaviour of prostate cancer cells embedded within it.
The mechanism is specific. Chronic hyperinsulinaemia activates IGF-1 signalling in prostate cancer cells, stimulating proliferation through AKT-PI3K and mTOR pathways. Chronically elevated mTOR suppresses the cellular quality-control cycles that would otherwise clear pre-malignant and low-grade malignant cells. Adipose-derived inflammation generates the cytokine environment that protects cancer cells from immune surveillance, promotes angiogenesis, and facilitates invasion.
At the molecular level, the AKT activation that chronic insulin excess produces drives a single protein, MDM2, into the cell nucleus. Once there, MDM2 does two things simultaneously: it suppresses p53, the cell's quality-control system, and it dysregulates androgen receptor turnover, sustaining the primary growth signal that defines the disease. One upstream metabolic cause. Two converging biological failures. Addressing the metabolic environment addresses both.
The clinical implication is that the decade or more of metabolic drift that precedes many prostate cancer diagnoses, declining insulin sensitivity, rising inflammatory tone, loss of metabolic oscillatory amplitude, is not clinically neutral. It is the period during which the field conditions were moving in the direction that prostate cancer progression favours. Population statistics for any given Gleason grade are averages across men with widely different metabolic fields. The average tells you the distribution. It does not tell you which field you have.
The hormonal ecology
Prostate cancer is, in its earliest and most treatable form, a disease of the androgen axis. This has been understood since Charles Huggins demonstrated in 1941 that castration produces remission in metastatic disease. The therapeutic corollary, that testosterone feeds prostate cancer and should therefore be suppressed, became so embedded in clinical orthodoxy that it persisted, essentially unchallenged, for six decades.
The problem is that Huggins' clinical finding was extrapolated far beyond what his data supported. His observation was that castration produces remission in advanced, metastatic, androgen-dependent prostate cancer. The inference that testosterone is therefore dangerous to men with prostate cancer at any stage, in any form, at physiological levels, was a logical extension that subsequent research has repeatedly failed to support.
Morgentaler's saturation model provided the corrective account. At physiological testosterone levels, the androgen receptor is already saturated, further increases in testosterone produce no additional stimulation of prostate cancer cell growth because the receptor is already fully occupied. It is only below the saturation threshold, in the castrate or severely hypogonadal state, that small changes in testosterone produce large changes in AR-mediated transcription and cancer cell behaviour. This is why the large TRAVERSE trial, the most comprehensive randomised controlled trial of testosterone replacement therapy ever conducted, found no increased risk of prostate cancer or prostate cancer progression in men receiving TRT.
The saturation model matters in two directions. Chronically low testosterone is not protective against prostate cancer, it is, according to the model, a permissive environment for it. The conventional narrative, testosterone feeds cancer, therefore suppress it, describes the biology of men with advanced metastatic disease. It does not describe the biology of early localised prostate cancer developing in a hypogonadal metabolic environment. For those men, the clinical orthodoxy may be pointing in precisely the wrong direction.
The oestrogen axis compounds this picture in ways that clinical practice almost never addresses. The ERalpha/ERbeta balance, intratumoral aromatase activity, the estrobolome's regulation of circulating oestrogen levels, and xenoestrogen interactions all contribute to a hormonal ecology that is shaped by individually specific conditions. Two men with the same testosterone level and the same Gleason score may have profoundly different ERalpha/ERbeta balance, different aromatase activity in their tumour microenvironment, and different TMPRSS2:ERG expression as a consequence. The diagnostic label is the same. The hormonal biology is not.
The microbial environment
One of the more striking developments in prostate cancer biology over the past decade is the characterisation of an intraprostatic microbiome, a community of microorganisms resident within prostate tissue itself that appears to influence both the tumour microenvironment and the hormonal conditions of the tissue in which cancer develops.
Cutibacterium acnes is the most prevalent organism identified, present in 60 to 87% of prostate tissue samples. Its presence is not incidental. C. acnes in prostate tissue drives local production of IL-6 and CXCL8, promotes PD-L1 expression on tumour cells, and recruits regulatory T cells, creating an immunosuppressive tumour microenvironment that protects cancer cells from immune surveillance. Microbial androgen biosynthesis within the tumour microenvironment, bacteria converting adrenal precursors to active androgens, may sustain AR signalling under castration conditions, contributing to the castration-resistant transition in advanced disease.
This biology is individually variable in ways that no population statistic can capture. The composition of the intraprostatic microbiome differs between men, is shaped by systemic gut microbiome composition, and is almost certainly affected by the metabolic and hormonal conditions of the tissue in which it is embedded. The clinical encounter that assesses prostate cancer, PSA, biopsy, staging scan, has no mechanism for asking about any of this.
Three diseases, one label
The most important structural fact about prostate cancer, and the one most consistently obscured by population statistics, is that it is not one disease. It is three biologically distinct diseases that share a diagnostic label.
The first is the silent reservoir: the large proportion of men who harbour histological prostate cancer that will never progress, never cause symptoms, and never require treatment. Autopsy data establishes this population as the majority of men who carry the disease. They die with it, not of it.
The second is slow biological disease: the larger fraction of clinically detected prostate cancers that progress over timescales measured in years to decades, shaped by the metabolic and hormonal field conditions this article has been examining. These are the men for whom the question is not whether to treat the cancer but how to understand the conditions under which it is behaving and whether those conditions can be modified.
The third is the aggressive minority: approximately 20% of clinically significant prostate cancers that progress rapidly, invade locally, and metastasise. These men need the population framework. They need randomised controlled trial evidence about which treatments reduce mortality. For them, the gap between population medicine and individual biology is smallest, because the disease is pressing hard enough that the specific conditions of the individual matter less than the urgent need to suppress the malignancy.
The problem with applying population statistics uniformly across all three categories is that it optimises clinical decision-making for the aggressive minority, the group that is rarest, most visible, most frightening, and for whom the population framework is most appropriate, while systematically mismanaging the slow biological majority, who need individual biological assessment rather than population-averaged treatment recommendations.
Current prostate cancer practice is structurally calibrated to the subgroup least representative of what most men with this diagnosis actually have. The framework is not wrong for the minority. It is misapplied to the majority.
The oscillation principle
Health, in biological terms, is the capacity for appropriate oscillation, the ability of a system to move when movement is required and return when return is appropriate. Prostate cancer, in its most common presentation, is a disease whose biological environment has lost the oscillatory conditions that would otherwise contain it.
The evidence comes from multiple directions. Intermittent androgen deprivation therapy, cycling between androgen suppression and testosterone recovery, produces outcomes comparable to continuous ADT in appropriately selected patients, while preserving hormonal recovery periods that maintain quality of life, protect bone density, and may preserve the testosterone sensitivity that continuous ADT eventually eliminates. The oscillation produces biological effects that continuous suppression does not.
Bipolar androgen therapy is the most dramatic clinical expression of this principle. In men whose prostate cancer has fully adapted to castrate conditions, developing castration resistance through the adaptive androgen receptor overexpression that chronic deprivation selects for, the deliberate restoration of supraphysiological testosterone kills the adapted cells through mechanisms that depend specifically on their adapted state. The cancer that learned to survive without oscillation is killed by its return. The TRANSFORMER trial's crossover data, BAT followed by enzalutamide producing PSA50 rates of 78% compared to 25% for enzalutamide alone, is not merely an interesting clinical finding. It is a demonstration that restoring oscillation can reset the biological state of a cancer that had progressed beyond the reach of further suppression.
For early, localised prostate cancer, the situation most men with this diagnosis actually face, the oscillation argument points in a different direction but toward the same principle. The cancer is not yet castration-resistant. The hormonal, metabolic, and microbial field conditions that will determine whether it progresses are not yet fixed. The oscillatory systems that would contain it, immune surveillance, cellular quality-control cycles, the metabolic rhythm that determines whether the microenvironment is permissive or resistant to progression, are impaired but potentially restorable.
The cancer that progresses is the cancer in a field that has lost its oscillatory capacity. Restoring the field does not guarantee the outcome. Ignoring it shapes the trajectory.
What individual assessment actually means
If the population framework, Gleason score, PSA, risk category, standard treatment algorithm, is necessary but insufficient for understanding an individual's prostate cancer, what does the sufficient account look like?
The metabolic field assessment begins with insulin sensitivity, not just fasting glucose or HbA1c; inflammatory tone through high-sensitivity CRP or IL-6; and body composition, specifically visceral adiposity rather than BMI. These are not exotic measurements. They require a slightly more comprehensive blood panel and a DEXA scan. They are not part of the standard prostate cancer assessment, but they describe conditions that substantially determine whether the disease will progress.
The hormonal ecology assessment extends beyond PSA and testosterone to include free and total testosterone trajectory rather than a single cross-sectional measurement; oestradiol and its relationship to testosterone through aromatase activity; and SHBG as a determinant of free hormone availability. This picture allows the identification of patterns, chronically low testosterone, elevated aromatisation, disrupted oestrogen clearance, that the single PSA measurement cannot see.
The individual natural history, the trajectory rather than the snapshot, is perhaps the most important element that standard assessment omits. A man whose PSA has been stable at 4.2 for three years is in a different biological situation from a man whose PSA has risen from 2.1 to 4.2 over the same period, even if their current values place them in the same risk category. PSA kinetics, velocity, doubling time, and curvature across the full series, provide the trajectory information that cross-sectional values cannot.